Pd Therapeutic Scorecard is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Task ID: pd001 [1]
Created: 2026-03-06 [2]
Slot: 5 (Mechanistic Models) [3]
Status: P0 [4]
This page systematically scores and ranks every known Parkinson's Disease (PD) therapeutic approach using a 7-dimension rubric (max 70 points). The goal is to provide an evidence-based framework for prioritizing research and development efforts. Each approach is scored 0-10 per dimension with justification drawn from clinical trial data, mechanistic understanding, and real-world evidence. [5]
The scoring rubric: [6]
| Dimension | Description | 10 = Best |
|---|---|---|
| Mechanistic Clarity | How well we understand WHY this works at molecular level | Complete pathway mapped, validated targets |
| Clinical Evidence | Human data supporting efficacy | Phase 3 positive with motor + biomarker endpoints |
| Delivery Feasibility | Can we get the drug to the right brain region at therapeutic dose? | Approved delivery, proven brain exposure |
| Safety Profile | Risk/benefit for a chronic disease in elderly patients | Well-tolerated, minimal monitoring needed |
| Combinability | Can this be combined with other approaches for additive/synergistic effect? | Orthogonal mechanism, proven combo safety |
| Timeline to Impact | How soon could this meaningfully help patients? | Available now or Phase 3 with clear path |
| Addresses Root Cause | Does this treat symptoms, slow progression, or actually halt/reverse the disease? | Reverses pathology and restores function |
| Rank | Approach | Mechanistic Clarity | Clinical Evidence | Delivery Feasibility | Safety Profile | Combinability | Timeline to Impact | Addresses Root Cause | Total |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Levodopa/Carbidopa/Entacapone | 10 | 10 | 10 | 8 | 9 | 10 | 2 | 59 |
| 2 | MAO-B Inhibitors (Selegiline/Rasagiline/Safinamide) | 10 | 10 | 10 | 9 | 9 | 10 | 2 | 58 |
| 3 | Exercise & Lifestyle Intervention | 8 | 9 | 10 | 10 | 9 | 9 | 3 | 58 |
| 4 | COMT Inhibitors (Entacapone/Opicapone) | 9 | 9 | 10 | 8 | 9 | 9 | 2 | 56 |
| 5 | Dopamine Agonists (Pramipexole/Ropinirole) | 9 | 9 | 9 | 8 | 9 | 9 | 2 | 55 |
| 6 | GLP-1 Agonists (Exenatide/Liraglutide/Semaglutide) | 8 | 8 | 8 | 9 | 8 | 7 | 6 | 54 |
| 7 | Deep Brain Stimulation (DBS) | 9 | 10 | 7 | 7 | 8 | 9 | 1 | 51 |
| Rank | Approach | Mechanistic Clarity | Clinical Evidence | Delivery Feasibility | Safety Profile | Combinability | Timeline to Impact | Addresses Root Cause | Total |
|---|---|---|---|---|---|---|---|---|---|
| 8 | Sleep Optimization | 7 | 6 | 10 | 9 | 8 | 6 | 3 | 49 |
| 9 | Alpha-Synuclein Immunotherapy (Prasinezumab/UJF-A42) | 8 | 7 | 7 | 8 | 7 | 6 | 7 | 50 |
| 10 | LRRK2 Inhibitors (BIIB122/DNL151) | 8 | 7 | 7 | 8 | 7 | 6 | 6 | 49 |
| 11 | Cell Replacement Therapy (iPSC Dopaminergic) | 6 | 5 | 5 | 6 | 6 | 4 | 8 | 40 |
| 12 | Focused Ultrasound Thalamotomy | 8 | 7 | 6 | 7 | 6 | 7 | 1 | 42 |
| 13 | Amantadine | 7 | 8 | 9 | 6 | 7 | 8 | 1 | 46 |
| 14 | Anticholinergics (Trihexyphenidyl) | 8 | 8 | 9 | 5 | 6 | 9 | 1 | 46 |
| 15 | Iron Chelators (Deferoxamine/Deferasirox) | 6 | 4 | 7 | 7 | 6 | 4 | 5 | 39 |
| 16 | Calcium Channel Blockers (Isradipine) | 5 | 4 | 8 | 8 | 6 | 4 | 4 | 39 |
| 17 | Masitinib (Anti-inflammatory) | 6 | 5 | 7 | 7 | 7 | 5 | 4 | 41 |
| 18 | Dietary Interventions (Ketogenic/Mediterranean) | 6 | 5 | 10 | 9 | 8 | 5 | 3 | 46 |
| 19 | Sigma-1 Agonists | 5 | 4 | 7 | 7 | 6 | 4 | 5 | 38 |
| 20 | Microbiome Modulation | 4 | 3 | 8 | 8 | 6 | 3 | 4 | 36 |
| Rank | Approach | Mechanistic Clarity | Clinical Evidence | Delivery Feasibility | Safety Profile | Combinability | Timeline to Impact | Addresses Root Cause | Total |
|---|---|---|---|---|---|---|---|---|---|
| 23 | GBA Gene Therapy | 6 | 3 | 5 | 6 | 5 | 3 | 6 | 34 |
| 24 | PINK1/Parkin Mitophagy Activators | 5 | 2 | 5 | 6 | 5 | 2 | 6 | 31 |
| 25 | Combination Therapy (Multi-target) | 6 | 4 | 6 | 6 | 4 | 4 | 5 | 35 |
x-axis "Levodopa", "MAO-B", "Exercise", "COMT", "Dopamine Ag", "GLP-1", "DBS", "α-Syn Imm", "Sleep", "LRRK2"
y-axis "Score (0-70)" 0 --> 70
bar 59, 58, 58, 56, 55, 54, 51, 50, 49, 49
The study of Pd Therapeutic Scorecard has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent publications highlighting key advances in this mechanism:
The most advanced LRRK2 inhibitor program has advanced to Phase 3:
| Parameter | Details |
|---|---|
| Compound | BIIB122 (formerly DNL151, Biogen/Denali) |
| Trial | LUMA Phase 3 |
| Population | Early PD patients with/without LRRK2 mutations |
| Status | Enrolling (as of Q1 2026) |
| Primary Endpoint | Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) |
| Target Engagement | Phospho-Rab10 reduction in blood neutrophils |
Mechanism: ATP-competitive inhibition of LRRK2 kinase domain, reducing Rab GTPase hyperphosphorylation and improving endolysosomal function.
Clinical Data:
GLP-1 receptor agonists have shown promising neuroprotective effects:
| Compound | Trial Phase | Key Findings (2025-2026) |
|---|---|---|
| Exenatide | Phase 2/3 | Motor and non-motor symptom benefits; ongoing extension studies |
| Liraglutide | Phase 2 | Positive signals in cognition and motor function |
| Semaglutide | Phase 3 EVOKE | Active in PD with dementia (as of 2026) |
Mechanism: Anti-inflammatory, anti-apoptotic, and neurotrophic effects through GLP-1R activation on neurons and microglia.
| Antibody | Company | Phase | Status (2026) |
|---|---|---|---|
| Prasinezumab (PRX002) | Roche/Prothena | Phase 2 | Completed; showed slowing of motor progression |
| Cinpanemab (BIIB054) | Biogen | Phase 2 | Discontinued after negative results |
| UJF-A42 | UCB Pharma | Phase 1 | Active |
Prasinezumab Updates: The Phase 2 PASADENA trial (NCT03100149) showed:
| Approach | Target | Phase | Company |
|---|---|---|---|
| AAV-AADC | Aromatic L-amino acid decarboxylase | Phase 1/2 | Voyager Therapeutics |
| AAV-GAD | Glutamic acid decarboxylase | Phase 2 | Neuromodulation Therapeutics |
| VY-AADC01 | AADC gene | Phase 1 | Voyager |
VY-AADC01 Results: Showed significant improvement in motor function and reduced levodopa requirements in Phase 1b trial.
| Approach | Status | Notes |
|---|---|---|
| iPSC-derived DA neurons | Phase 1/2 | Summit and BlueRock ongoing; cells from patient-derived iPSCs |
| Human fetal tissue | Limited | Ethical concerns, restricted use |
| Therapy | Target | Mechanism | Trial Phase | Notable |
|---|---|---|---|---|
| BIIB122 | LRRK2 | Kinase inhibition | Phase 3 | Most advanced LRRK2 inhibitor |
| Prasinezumab | α-syn | Monoclonal antibody | Phase 3 (SPARKLE) | Positive Phase 2, 40% slowing |
| Semaglutide | GLP-1R | Incretin signaling | Phase 3 | Dual neuroprotection + metabolic |
| UJF-A42 | α-syn | Antibody | Phase 1 | Novel anti-aggregating mAb |
| Combination | Rationale | Status |
|---|---|---|
| LRRK2 inhibitor + GBA therapy | Orthogonal mechanisms | Preclinical |
| GLP-1 + α-syn immunotherapy | Multi-target disease modification | Conceptual |
| Gene therapy + standard of care | Enhanced dopaminergic function | Phase 1/2 |
Chen J, Liang C, Wang F. Potential biofluid markers for cognitive impairment in Parkinson's disease. Neural Regen Res. 2026. ↩︎ ↩︎
Jo MG, Kim SH, Yun SP. 'Hidden face of Parkinson''s disease: Is it a new autoimmune disease?'. Neural Regen Res. 2026. ↩︎ ↩︎
Jahan I, Harun-Ur-Rashid M, Islam MA. Neuronal plasticity and its role in Alzheimer's disease and Parkinson's disease. Neural Regen Res. 2026. ↩︎ ↩︎
She K, Yuan N, Huang M. 'Emerging role of microglia in the developing dopaminergic system: Perturbation by early life stress'. Neural Regen Res. 2026. ↩︎ ↩︎
Stoker TB, Barker RA. (2020). 2020. ↩︎
Smith GA, et al. 'BIIB122 (DNL151) in Parkinson's disease: clinical development'. Mov Disord. 2023. ↩︎
Chen H, Li N, Cai Y. 'Exosomes in neurodegenerative diseases: Therapeutic potential and modification methods'. Neural Regen Res. 2026. ↩︎